As of May 30, 2026, Ultragenyx Pharmaceutical's top three insider holders are Emil D Kakkis (President Ceo, 2.22Mn shares), Emil D Kakkis (President Ceo, 2.16Mn shares), Emil D Kakkis (President Ceo, 735.74K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Daniel G Welch | - | 32,690 | 0 | 19 May, 2025 |
| Emil D Kakkis | President Ceo | 0 | 2,223,985 | 05 Sep, 2024 |
| Thomas Richard Kassberg | Cbo Evp | 264,730 | 0 | 04 Mar, 2025 |
| Camille L Bedrosian | Evp And Chief Medical Officer | 46,720 | 0 | 03 Mar, 2023 |
| Deborah Dunsire | - | 30,815 | 0 | 19 May, 2025 |
| Lars Ekman | - | 17,745 | 0 | 28 Jun, 2022 |
| Michael Narachi | - | 32,690 | 0 | 19 May, 2025 |
| Matthew K Fust | - | 25,945 | 0 | 19 May, 2025 |
| Mardi Dier | Cfo Executive Vice President | 66,695 | 0 | 17 Oct, 2022 |
| Theodore Alan Huizenga | Svp, Chief Accounting Officer | 68,911 | 0 | 24 Apr, 2026 |
| Dennis Karl Huang | - | 147,845 | 0 | 20 Apr, 2026 |
| John Richard Pinion | - | 133,142 | 0 | 20 Apr, 2026 |
| Eric Crombez | Evp And Chief Medical Officer | 110,975 | 0 | 20 Apr, 2026 |
| Karah Herdman Parschauer | Evp And Chief Legal Officer | 95,715 | 0 | 20 Apr, 2026 |
| Shehnaaz Suliman | - | 25,940 | 0 | 19 May, 2025 |
| Erik Harris | Evp Chief Commercial Officer | 118,410 | 0 | 20 Apr, 2026 |
| Howard Horn | Chief Financial Officer | 115,025 | 0 | 20 Apr, 2026 |
| Corazon (Corsee) D. Sanders | - | 15,344 | 0 | 23 Jun, 2025 |
| Amrit Ray | - | 23,365 | 0 | 19 May, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 22 Apr, 2026 | Theodore Alan Huizenga | Common Stock | A | 20,241 | $0.00 | 68,911 | D | A |
| 22 Apr, 2026 | Theodore Alan Huizenga | Stock Option (Right to Buy) | A | 7,348 | $0.00 | 7,348 | D | A |
| 16 Apr, 2026 | Eric Crombez | Common Stock | A | 34,674 | $0.00 | 110,975 | D | A |
| 16 Apr, 2026 | Karah Herdman Parschauer | Common Stock | A | 28,895 | $0.00 | 95,715 | D | A |
| 16 Apr, 2026 | Dennis Karl Huang | Common Stock | A | 23,116 | $0.00 | 147,845 | D | A |
| 16 Apr, 2026 | John Richard Pinion | Common Stock | A | 23,116 | $0.00 | 133,142 | D | A |
| 16 Apr, 2026 | Emil D Kakkis | Common Stock | A | 76,745 | $0.00 | 735,739 | D | A |
| 16 Apr, 2026 | Howard Horn | Common Stock | A | 34,674 | $0.00 | 115,025 | D | A |
| 16 Apr, 2026 | Erik Harris | Common Stock | A | 28,895 | $0.00 | 118,410 | D | A |
| 16 Apr, 2026 | John Richard Pinion | Stock Option (Right to Buy) | A | 79,936 | $0.00 | 79,936 | D | A |
| 16 Apr, 2026 | Eric Crombez | Stock Option (Right to Buy) | A | 59,952 | $0.00 | 59,952 | D | A |
| 16 Apr, 2026 | Karah Herdman Parschauer | Stock Option (Right to Buy) | A | 49,960 | $0.00 | 49,960 | D | A |
| 16 Apr, 2026 | Dennis Karl Huang | Stock Option (Right to Buy) | A | 79,936 | $0.00 | 79,936 | D | A |
| 16 Apr, 2026 | Erik Harris | Stock Option (Right to Buy) | A | 49,960 | $0.00 | 49,960 | D | A |
| 16 Apr, 2026 | Howard Horn | Stock Option (Right to Buy) | A | 59,952 | $0.00 | 59,952 | D | A |
| 16 Apr, 2026 | Emil D Kakkis | Stock Option (Right to Buy) | A | 132,693 | $0.00 | 132,693 | D | A |
| 01 Apr, 2026 | Howard Horn | Common Stock | D | 4,683 | $20.97 | 80,351 | D | S |
| 06 Mar, 2026 | Karah Herdman Parschauer | Common Stock | D | 6,018 | $21.40 | 70,328 | D | S |
| 10 Mar, 2026 | Karah Herdman Parschauer | Common Stock | D | 3,508 | $22.67 | 66,820 | D | S |
| 01 Mar, 2026 | Erik Harris | Common Stock | A | 11,643 | $0.00 | 99,498 | D | A |